C5 Complement
EstablishedC5 initiates the terminal complement pathway; its deficiency causes selective susceptibility to Neisseria infections.
C5 starts the final stage of the complement system, which punches holes in bacteria. Missing it leads to a very specific weakness: repeated infections from a particular bacteria family (Neisseria), while other infection risks stay roughly normal.
C5 is the first component of the terminal complement pathway, cleaved to form C5a (a potent inflammatory signal) and C5b, which initiates assembly of the membrane attack complex (MAC) that punctures bacterial cell walls.
C5 deficiency, like other terminal (C5-C9) complement deficiencies, causes a distinct susceptibility pattern: recurrent Neisseria infections (meningococcal meningitis, disseminated gonococcal infection), often with unusual serotypes, while these patients are not especially prone to infections generally otherwise.
Screened via CH50 and AH50 (both abnormal, since C5 is downstream of both pathways), followed by specific terminal complement component assays to identify which of C5-C9 is deficient.
Vaccination against Neisseria meningitidis is essential in confirmed terminal complement deficiencies; C5 is also the target of the complement-inhibitor drug eculizumab, used therapeutically in other conditions like paroxysmal nocturnal hemoglobinuria.
Also a therapeutic drug target (eculizumab) in unrelated complement-mediated diseases.
- StatPearls. (2023). Complement Deficiency — Treatment & Management.